DSM Invests in Personalized Healthcare Company IntegraGen SA
IntegraGen focuses on the medical/pharma side of personalized healthcare but recognizes the potential of its know how in personalized nutrition, one of the emerging business areas DSM focuses on to realize its longer-term innovation ambitions.
07/11/06 DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has invested EUR 2 mln in IntegraGen, a French biotechnology company specialized in the development and delivery of genetic tests for rapid diagnosis and better (personalized) treatment of complex diseases.
IntegraGen’s proprietary GenomeHIP technology platform identifies disease genes by allowing the rapid comparison of genomes of family members affected with the same disease. Using this platform IntegraGen has established a pipeline of tests in the areas of Metabolic Syndrome (e.g. MODY (Maturity Onset Diabetes of the Young); Type 2 Diabetes; Obesity) and Neuropsychiatric disorders (e.g. Autism; Bi-Polar Disorder).
IntegraGen focuses on the medical/pharma side of personalized healthcare but recognizes the potential of its know how in personalized nutrition, one of the emerging business areas DSM focuses on to realize its longer-term innovation ambitions as formulated in the corporate strategy program Vision 2010 – Building on Strengths.
This joint interest has led to a collaboration program in the area of weight management, which is one of the important focus areas within the field of Personalized Nutrition.
Following DSM’s acquisition of Lipid Technologies Provider and the investment in Sciona, this investment is a next stepping stone in weight management and Personalized Nutrition, which moves DSM into an excellent position for future developments in these fields.
